I expect the EU will work a bit faster on its pre-orders from now on.
That's where it went wrong. If the drug company knows it has the sale, it can invest in its manufacturing facilities upfront.
The UK also now knows it can't rely on EU manufacturers, so will make sure all of its manufacturing is done locally and that the companies cannot have overlapping demands from the EU (because it queue-barges).